Non-steroidal ligands for steroid hormone receptors

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 4, 2000, Pages 383-398

  Xiaodong, Lin ^a   Huebner, Verena ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Androgen receptor; Estrogen receptor; Ligand; Progesterone receptor; Steroid hormone receptors

Indexed keywords

1 (3,4 DICHLOROBENZOYL) 1,4,5,6 TETRAHYDRO 3 PHENYLPYRIDAZINE; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ARZOXIFENE; BAZEDOXIFENE; BICALUTAMIDE; CHIR 029122; DROLOXIFENE; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; FLUTAMIDE; GW 5836; GW 5838; HYDROXYTAMOXIFEN; IDOXIFENE; LG 001447; LG 100127; LG 100128; LG 120746; LG 120830; LY 357489; MIPROXIFENE PHOSPHATE; NILUTAMIDE; PF 1092A; PROGESTERONE RECEPTOR; RALOXIFENE; STEROID HORMONE RECEPTOR BLOCKING AGENT; STEROID RECEPTOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG DESIGN; DRUG INDICATION; DRUG STRUCTURE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 0033940430     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: The second decade. Cell (1995) 83(6):835-839.
2. Beato M, Herrlich P, Schutz G: Steroid hormone receptors: Many actors in search of a plot. Cell (1995) 83(6):851 -857.
3. Mosselman S, Polman J, Dijkema R: ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 392(1 ):49-53. Initial identification of ERβ in human tissue; analysis of distribution in human tissues by Northern blot.
4. Kuiper CG, Cartsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J-A: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and β. Endocrinology (1997) 138(3):863-870.
5. Couse JF, Korach KS: Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev (1999)20(3):358-417. An extensive review of data obtained to date on aERKO and βERKO mice. The study of these animals will give valuable insights into the tissue-selective roles of the two ER receptor subtypes.
6. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Onman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389{6652):753-758.
7. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 95(7):927-937. An elegant study showing the structural basis of the interaction of ERcc with a co-activator peptide and how the structural changes induced by tamoxifen eliminate this interaction.
8. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson J, Carlquist M: Structure of the ligand-binding domain of oestrogen receptor βin the presence of a partial agonist and a full antagonist. EMBO J(1999) 18(17):4608-4618.
9. MacGregor Jl, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev (1998) 50(2):151-196. An extensive review of the field of anti-estrogens from the very earliest anti-estrogens to raloxifene and present day SERMs.
10. Sato M, Grese TA, Dodge JA, Bryant HU, Turner CH: Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem (1999) 42(1 ):1 -24.
11. Cosman F, Lindsay R: Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev (1999) 20(3):418-434. Reviews the clinical effects of two SERMs, raloxifene and tamoxifen, comparing the clinical data available for both drugs.
12. Grese TA, Dodge JA: Selective estrogen receptor modulators (SERMs). CurrPharm Des (1998) 4(1):71-92.
13. Jordan VC: Tamoxifen treatment for breast cancer: Concept to gold standard. Oncology (1997) 11(2 Suppl 1):7-13.
14. Early Breast Cancer Trialists1 Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. J.ance/(1998) 351:1451-1467.
15. Jordan VC: Estrogen receptor as a target for the prevention of breast cancer. J Lab Clin Med (1999) 133(5):408-414.
16. Haynes B, Dowsett M: Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging (1999) 14(5):323-336.
17. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst (1998) 90(18):1371-1388.
18. Buzdar AU, Hortobagyi GN: Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. J Clin Onco/(1998) 16(1):348-353.
19. Hard GC, lalropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female CrhCD(BR) rats. Cancer Res (1993) 53(19):4534-4541.
20. Toko T, Shibata J, Sugimoto Y, Yamaya H, Yoshida M, Ogawa K, Matsushima E: Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Cancer Chemother Pharmacol (1995) 37(1-2):7-13.
21. Nomura Y, Nakajima M, Tominaga T, Abe O: Late phase II study of TAT-59 (miproxifene phosphate) In advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate). Jpn J Cancer Chemother (1998) 25(7):1045-1063.
22. Aoyama H, Tominaga T, Abe O: Early phase II study of TAT59 in patients with advanced or recurrent breast cancer - a multicenter dose finding study. Jpn J Cancer Chemother (1998)25(6):853-865.
23. Willson TM, Morris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC, McDonnell DP: Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology (1997) 138(9):3901-3911.
24. Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn, DB, Moore LB, Oliver BB, Sauls HR, Triantafillou JA, Wolfe SG, Baer PG: 3-[4-{1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem (1994) 37(11):1550-1552.
25. Ruenitz PC, Bourne CS, Sullivan KJ, Moore SA: Estrogenic triarylethylene acetic acids: Effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells. J Med Chem (1996) 39(24):4853-4859.
26. Kraft KS, Ruenitz PC, Bartlett MG: Carboxylic acid analogues of tamoxifen: (2)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-/V,W-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells. J Med Chem (1999) 42(16):3126-3133.
27. Delmas PD, Bjamason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Chirstiansen C: Effects of raloxifene on bone mineral density serum cholesterol concentrations and uterine endometrium in postmenopausal women. New EnglJ Med (1997) 337(23):1641-1647.
28. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L Jr: Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol (2000) 95(1):104-110.
29. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjamason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAm Med Assoc (1999) 281 (23):2189-2197.
30. Sato M, Grese TA, Dodge JA, Bryant HU, Turner CH: Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem (1999) 42(1):1-24.
31. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant HU: Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: A novel, highly potent, selective estrogen receptor modulator. J Med Chem (1997) 40(10):1407-1416.
32. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU: LY353381.HCI: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther (1998)287(1):1-7.
33. Sato M, Zeng GQ, Rowley E, Turner CH: LY353381HCI: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34). Endocrinology (1998) 139(11 ):4642-4651.
34. Schmid CR, Glasebrook AL, Misner JW. Stephenson GA: Synthesis and biological activity of trans-2,3dihydroraloxifene. Bioorg Med Chem Lett (1999) 9(8):1137-1140.
35. Grese TA, Pennington LD, Sluka JP, Adrian MD, Cole HW, Fuson TR, Magee DE, Phillips DL, Rowley ER, Shetler PK, Short LL, Venugopalan M, Yang NN, Sato M, Glasebrook AL, Bryant HU: Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators. J Med Chem (1998) 41(8):1272-1283.
36. Rosati RL, Da Silva JP, Cameron KO, Thompson DD, Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cde MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie CM, Qi H, Simmons HA, Tkalcevic GT: Discovery and preclinical pharmacology of a novel, potent, non-steroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. JMed Chem (1998) 41(16):2928-2931.
37. Sorbera LA, Leeson PA, Castaner J: CP-336156. Treatment of osteoporosis, estrogen receptor modulator. Drugs Future (1998) 23(10):1066-1070.
38. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD: Effects of CP-336,156, a new, non-steroldal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology (1998) 139(4):2068-2076.
39. Rotella DP: American Chemical Society 219th National Meeting - Selective estrogen receptor modulators. I Drugs (2000) 3(6):589-590.
40. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD: Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat Endocrinology (2000) 141 (4):1338-1344.
41. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Quellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F: (S)-(+)-4-[7-{2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2W-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active non-steroidal antiestrogen. J Med Chem (1997) 40(14):2117-2122.
42. Simard J, Labrie C, Bélanger A, Gauthier S, Singh SM, Mérand Y, Labrie F: Characterization of the effects of the novel nonsteroidal antiestrogen EM-800 on basal and estrogen-Induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells In vitro. IntJ Cancer(1997) 73(1):104-112.
43. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Merand Y, Belanger A, Labrie C, Labrie F: Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res (1997) 57(16):3494-3497.
44. Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguère V: EM800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and β. Endocrinology (1998) 139(1 ):111 -118.
45. Couillard S, Gutman M, Labrie F, Candas B, Labrie C: Effect of combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res (1999) 59(19):4857-4863.
46. Grese TA, Skyja JP, Bryant HU, Cole HW, Kirn JR, Magee DE, Rowley ER, Sato M: Benzopyran selective estrogen receptor modulators (SERMS): Pharmacological effects and structural correlation with raloxifene. Bioorg Med Chem Lett (1996) 6(7):903-908.
47. Fink BE, Mortensen DS, Stauffer SR, Aron ZD, Katzenellenbogen JA: Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol (1999) 6(4):205-219. Describes novel ER ligands discovered by means of rational design.
48. Conneely OM, Lydon JP, De Mayo F, O'Malley BW: Reproductive functions of the progesterone receptor. J Soc Gynecol Investig (2000) 7(Suppl 1 ):S25-S32.
49. Giangrande PH, McDonnell DP: The A and B isoforms of the human progesterone receptor: Two functionally different transcription factors encoded by a single gene. Recent Prog Horn Res (1999) 54:291-314. Describes the nature of the two progesterone receptor isoforms and the present theories about how they interact.
50. Gronemeyer H: Transcription activation by estrogen and progesterone receptors. Annu Rev Genet (1991) 25:89-123.
51. Vegelo E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP: Human progesterone receptor A form is a cell and promoter-specific represser of human progesterone receptor B function. Mol Endocrinol (1993) 7(10):1244-1255.
52. Kraus WL, Weis KE, Katzenellenbogen BS: Inhibitory cross talk between steroid hormone receptors: Differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist occupied progestin receptors. Mol Cell Biol (1995) 15(4):1847-1857.
53. Zhi L, Tegley CM, Marschke KB, Mais DE, Jones TK: 5-Aryl1,2,3,4-tetrahydrochromeno[3,4-/]quinolin-3-ones as a novel class of non-steroidal progesterone receptor agonists: Effect of A-ring modification. J Med Chem (1999) 42(8):1466-1472.
54. Zhi L, Tegley CM, Edwards JP, West SJ, Marschke KB, Gottardis MM, Mais DE, Jones TK: 5-aikyl 1,2-dihydrochromeno[3,4-J]quinolines: A novel class of non-steroidal progesterone receptor modulators. Bioorg Med Chem Lett (1998) 8(23):3365-3370.
55. Zhi L, Tegley CM, Kallel EA, Marschke KB, Mais DE, Gottardis MM, Jones TK: 5-Aryl-1,2-dihydrochromeno[3,4-Jfouinolines: A novel class of non-steroidal human progesterone receptor agonists. J Med Chem (1998) 41(3):291-302.
56. Tegley CM, Zhi L, Marschke KB, Gottardis MM, Yang Q, Jones TK: 5-Benzylidene 1,2-dihyrochromeno[3,4-i]quinolines, a novel class of non-steroidal human progesterone receptor agonists. J Med Chem (1998) 41 (22):4354-4359.
57. Edwards JP, West SJ, Marschke KB, Mais DE, Gottardis MM, Jones TK: 5-Aryl-1,2-dihydro-5H-chromeno[3,4-r]quinolines as potent, orally active, non-steroidal progesterone receptor agonists: The effect of D-f ing substituents. J Med Chem (1998) 41(3):303-310.
58. Edwards JP, Zhi L, Pooley CL, Tegley CM, West SJ, Wang M-W, Gottardis MM, Pathirana C, Schrader WT, Jones TK: Preparation, resolution and biological evaluation of 5-aryl1,2-dihydro-5W-chromeno[3,4-/]quinolines: Potent, orally active, non-steroidal progesterone receptor agonists. J Med Chem (1998) 41(15):2779-2785.
59. Pathirana C, Stein RB, Berger TS, Fenical W, laniro T, Mais DE, Torres A, Goldman ME: Non-steroidal human progesterone receptor modulators from the marine alga Cymopolia barbata. Mol Pharmacol (1995) 47(3):630-635.
60. Hamann LG, Farmer LJ, Johnson MG, Bender SL, Mais DE, Wang M-W, Crombie D, Goldman ME, Jones TK: Synthesis and biological activity of novel non-steroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether. J Med Chem (1996) 39(9):1778-1789.
61. Pooley CL, Edwards JP, Goldman ME, Wang M-W, Marschke KB, Crombie DL, Jones TK: Discovery and preliminary SAR studies of a novel, non-steroidal progesterone receptor antagonist pharmacophore. J Med Chem (1998) 41(18):3461-3466.
62. Hamann LG, Winn DT, Pooley CL, Tegley CM, West SJ, Farmer LJ, Zhi L, Edwards JP, Marschke KB, Mais DE, Goldman ME, Jones TK: Non-steroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl1,2-dihydro-2,2,4-trimethyiquinolines. Bloorg Med Chem Lett (1998) 8(19):2731-2726.
63. Kuriahara K, Tanabe K, Yamamoto Y, Shinei R, Ajito K, Okonogi T: Synthesis and structure-activity relationships of new non-steroidal progesterone receptor ligands. Bloorg Med Chem Lett (1999) 9(13):1837-1842.
64. Connoliy PJ, Wetter SK, Beers KN, Hamel SC, Haynes-Johnson D, Koddoe M, Kraft P, Lai MT, Campen C, Palmer S, Phillips A: Synthesis and progesterone receptor binding affinity of substituted 1-phenyl-7-benzyl-4,5,6,7-tetrahydro1-indazoles. Bioorg Med Chem Le«(1997) 7(19):2551-2556.
65. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 122(2):552-562.
66. Huggins C, Hodges CV: Studies on prostate cancer: The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res( 1941) 1:293-297.
67. Reid P, Kantoff P, Oh W: Antiandrogens in prostate cancer. Invest New Drugs (1999) 17(3):271-284.
68. Singh SM, Gauthier S, Labrie F: Androgen receptor antagonists (antiandrogens): Structure-activity relationships. Curr Med Chem (2000) 7(2):211 -247. Describes in detail the SAR of the known classes of androgen receptor antagonists.
69. Neri R, Rorance K, Koziol P, Van Cleave S: A biological profile of a non-steroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide). Endocrinology (1972) 91(8):427-437.
70. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D: Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. J Clin Onco/(1996) 14(8):2250-2257.
71. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Spano G: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study. J Clin Onco/(1999) 17(7):2027-2038.
72. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer (1995) 76(8):1428-1434.
73. Jenster G: The role of the androgen receptor in the development and progression of prostate cancer. Semin Onco/(1999) 26(4):407-421.
74. Hamann LG, Higuchi Rl, Zhi L, Edwards JP, Wang XN, Marschke KB, Kong JW, Farmer LJ, Jones TK: Synthesis and biological activity of a novel series of non-steroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-<;]quinolines. J Med Chem (1998) 41(4):623-639.
75. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK: New non-steroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1HJ-pyrrolidino[3,2-g]quinolinone. Bioorg Med Chem Lett (1998) 8(7):745-750.
76. Miyachi H, Azuma A, Kitamoto T, Hayashi K, Kalo S, Koga M, Sato B, Hashimoto Y: Potent novel non-steroidal androgen antagonists with a phthalimide skeleton. Bioorg Med Chem Lett (1997) 7(11 ):1483-1488.
77. Zhi L, Tegley CM, Marschke KB, Jones TK: Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorg Med Chem Lett (1999) 9(7):1009-1012.
78. Higuchi Rl, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, ArienS KL, Marschke KB, Davis RL, Farmer LJ, Jones TK: 4-alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: Potent, non-steroidal androgen receptor agonists. Bioorg Med Chem Lett (1999) 9(9):1335-1340.
79. Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK: Discovery of a potent, orally active, nonsteroldal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-{trifluoromethyl)-8-pyridono[5,6-g]-quinolone (LG121071). JMedOjem(1999)42(2):210-212.
80. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD: Discovery of non-steroidal androgens. Biochem Biophys Res Comm (1998) 244{1):1-4.